RVMD - Why Is Cancer Focused Revolution Medicines Stock Trading Higher Today? | Benzinga
Revolution Medicines Inc (NASDAQ: RVMD) released preliminary data for RMC-6236, its RASMULTI(ON) Inhibitor, and RMC-6291, its RASG12C(ON) Inhibitor, from the respective Phase 1/1b studies.
These data were presented during the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Phase 1/1b Trial of RMC-6236 as monotherapy in patients with advanced solid tumors harboring KRASG12X mutations.
- As of the September 11, 2023 data cut-off, RMC-6236 demonstrated an acceptable safety profile that was generally well tolerated across dose levels.
- RMC-6236 demonstrated dose-dependent increases in exposure at a steady ...